The impact of therapeutic Human Immunodeficiency Virus (HIV) vaccination followed by antiretroviral therapy in patients with prolonged viral suppressio

Completed

• Conditions: Human Immunodeficiency Virus (HIV); Infections and Infestations; Human immunodeficiency virus (HIV)

• Registration Number: ISRCTN87061665
• Lead Sponsor: Ottawa Hospital Research Institute (Canada)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-11-16
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. HIV positive CD4 greater than 500
2. Age 18 years and older, either sex
3. CD4 nadir greater than 250
4. Viral load less than 50 for greater than 2 years
5. Receiving a Protease Inhibitor (PI) or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)

Exclusion Criteria

1. Patients with previous Acquired Immunodeficiency Syndrome (AIDS) defining opportunistic infections, previous cancer chemotherapy or other system immunosuppressive therapy
2. Patients with concurrent infections with hepatitis C or hepatitis B or any other acute illness

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time to virologic rebound.